Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogenetics

Leuk Res. 2015 Aug;39(8):818-21. doi: 10.1016/j.leukres.2015.05.001. Epub 2015 May 14.

Abstract

The prognostic value of ferritin level at diagnosis in AML patients is unknown. We studied 162 younger AML patients with intermediate-risk cytogenetics who received intensive chemotherapy. The median ferritin level at diagnosis was 633 μg/L and 128 (79%) patients had a ferritin level above the upper normal limit. Hyperferritinemia was significantly associated with a higher cumulative incidence of relapse as well as poorer disease-free and overall survival. In multivariate analysis, hyperferritinemia remained an independent poor prognosis factor. The level of ferritin at diagnosis has a major impact on relapse suggesting a link between inflammation, oxidative stress and chemoresistance in AML.

Keywords: Acute myeloid leukemia; Ferritin; Leukemia; Prognosis.

MeSH terms

  • Adolescent
  • Adult
  • Cytogenetic Analysis
  • Female
  • Ferritins / blood*
  • Humans
  • Leukemia, Myeloid, Acute / blood*
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / mortality*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / blood*
  • Neoplasm Recurrence, Local / genetics
  • Neoplasm Recurrence, Local / mortality*
  • Prognosis
  • Recurrence
  • Retrospective Studies
  • Risk Factors
  • Survival Analysis
  • Young Adult

Substances

  • Ferritins